Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherNEUROPHARMACOLOGY

[(S)-Alpha-Phenyl-2-Pyridine-Ethanamine Dihydrochloride], A Low Affinity Uncompetitive N-Methyl-d-Aspartic Acid Antagonist, Is Effective in Rodent Models of Global and Focal Ischemia

Edward F. Cregan, James Peeling, Dale Corbett, Alastair M. Buchan, John Saunders, Roland N. Auer, M. Gao, Dennis J. Mccarthy, Mark S. Eisman, T. Mark Campbell, Robert J. Murray, Mary L. Stagnitto and Gene C. Palmer
Journal of Pharmacology and Experimental Therapeutics December 1997, 283 (3) 1412-1424;
Edward F. Cregan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Peeling
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dale Corbett
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alastair M. Buchan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Saunders
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roland N. Auer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Gao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dennis J. Mccarthy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark S. Eisman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Mark Campbell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert J. Murray
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary L. Stagnitto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gene C. Palmer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

[(S)-Alpha-phenyl-2-pyridine-ethanamine dihydrochloride] (ARL 15896AR) is a low affinity uncompetitive N-methyl-d-aspartic acid receptor antagonist that was tested in animal models of anoxia and ischemia. Pretreatment of rodents with ARL 15896AR extended survival time during exposure to hypoxia. With the rat four-vessel occlusion model of global ischemia (20 min), oral dosing commencing at reflow, resulted in significant protection of the CA1 hippocampal neurons. ARL 15896AR was, however, ineffective in the rat two-vessel occlusion model and in the gerbil models of forebrain ischemia, the latter due to an inability to attain suitable plasma levels. In the spontaneously hypertensive rat model of middle cerebral artery occlusion (MCAO) (2 hr plus 22 hr reflow), acute dosing with ARL 15896AR (i.p.) beginning from 30 min before or up to 1 hr post-MCAO significantly reduced cortical infarct volume. The ability of ARL 15896AR to influence infarct size, as well as functional correlates was examined in SHR after 90 min of MCAO. T2weighted magnetic resonance images taken at 2 and 6 days post-MCAO revealed significantly smaller lesion sizes in the group receiving injections with ARL 15896AR beginning 30 min after occlusion. Spontaneously hypertensive rats were subsequently tested (30–42 days post-MCAO) and found to be deficient in skilled use of the forepaws (staircase test). The contralateral forepaw was most severely impaired, however, ARL 15896AR treatment prevented motor impairment in only the ipsilateral forepaw. Histopathological examination of cortical infarct size was unremarkable between treated and control rats. The findings indicate that ARL 15896AR exhibits neuroprotection in global and focal models of ischemia

Footnotes

  • Send reprint requests to: Dr. Gene C. Palmer, Astra Arcus USA, P.O. Box 20890, Rochester, NY 14602.

  • ↵1 This work was supported by the “Astra/Canada Neurodegenerative Network” collaborative research program, Astra Pharma Inc, Mississauga, Ontario, Canada.

  • Abbreviations:
    ANOVA
    analysis of variance
    ARL 15896AR
    [(S)-alpha-phenyl-2-pyridine-ethanamine dihydrochloride]
    AUC
    area under the curve
    b.i.d.
    twice a day dosing
    CBF
    cerebral blood flow
    Cmax, maximal plasma concentration
    H & E, hematoxylin and eosin
    MCA
    middle cerebral artery
    MCAO
    middle cerebral artery occlusion
    MRI
    magnetic resonance imaging
    NMDA
    N-methyl-d-aspartic acid
    SHR
    spontaneously hypertensive rat
    t1/2, plasma half life
    Tmax, time to peak plasma concentration
    V/f
    volume of distribution/fraction absorbed
    2-VO
    2-vessel occlusion
    4-VO
    4-vessel occlusion
    • Received January 22, 1997.
    • Accepted July 8, 1997.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 283, Issue 3
1 Dec 1997
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
[(S)-Alpha-Phenyl-2-Pyridine-Ethanamine Dihydrochloride], A Low Affinity Uncompetitive N-Methyl-d-Aspartic Acid Antagonist, Is Effective in Rodent Models of Global and Focal Ischemia
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherNEUROPHARMACOLOGY

[(S)-Alpha-Phenyl-2-Pyridine-Ethanamine Dihydrochloride], A Low Affinity Uncompetitive N-Methyl-d-Aspartic Acid Antagonist, Is Effective in Rodent Models of Global and Focal Ischemia

Edward F. Cregan, James Peeling, Dale Corbett, Alastair M. Buchan, John Saunders, Roland N. Auer, M. Gao, Dennis J. Mccarthy, Mark S. Eisman, T. Mark Campbell, Robert J. Murray, Mary L. Stagnitto and Gene C. Palmer
Journal of Pharmacology and Experimental Therapeutics December 1, 1997, 283 (3) 1412-1424;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
OtherNEUROPHARMACOLOGY

[(S)-Alpha-Phenyl-2-Pyridine-Ethanamine Dihydrochloride], A Low Affinity Uncompetitive N-Methyl-d-Aspartic Acid Antagonist, Is Effective in Rodent Models of Global and Focal Ischemia

Edward F. Cregan, James Peeling, Dale Corbett, Alastair M. Buchan, John Saunders, Roland N. Auer, M. Gao, Dennis J. Mccarthy, Mark S. Eisman, T. Mark Campbell, Robert J. Murray, Mary L. Stagnitto and Gene C. Palmer
Journal of Pharmacology and Experimental Therapeutics December 1, 1997, 283 (3) 1412-1424;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Methods
    • Histological Procedures
    • Results
    • Discussion
    • Conclusion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Oxysterols and ethanol
  • P-glycoprotein Apical Efflux Ratio for Compound Optimization
  • Pharmacology of Carbamate Insecticides at MT1 & MT2
Show more Neuropharmacology

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics